Repatha vs Lisinopril: Cost and Access Head-to-Head

Why These Two Drugs Get Compared

Patients with atherosclerotic cardiovascular disease (ASCVD) or multiple cardiometabolic risk factors often need both LDL-C reduction and blood pressure control. Repatha and lisinopril address different physiologic targets but frequently appear on the same medication list. The comparison matters because one drug costs over 100 times more than the other, and access barriers differ radically.

This is not a direct head-to-head efficacy comparison. No randomized trial has tested evolocumab against lisinopril because they treat different conditions. The FOURIER trial (Sabatine et al., NEJM 2017) tested evolocumab added to statin therapy in patients with established ASCVD. The ALLHAT trial (JAMA 2002) compared lisinopril against chlorthalidone and amlodipine for hypertension management. Synthesizing cost and access data across these two drugs helps clinicians and patients set realistic expectations for out-of-pocket burden and formulary navigation.

Cost Breakdown: List Price vs Real-World Out-of-Pocket

Repatha carries a wholesale acquisition cost (WAC) of approximately $5,850 annually. After Amgen's copay assistance program (the Repatha Ready card), commercially insured patients may pay as little as $5 per month, but this program excludes Medicare Part D and Medicaid beneficiaries. For Medicare patients without Extra Help, the specialty tier copay can exceed $300-$500 per fill during the coverage gap phase (Centers for Medicare & Medicaid Services, 2024).

Lisinopril costs between $4 and $15 for a 30-day supply at most retail pharmacies. Multiple big-box and grocery chains include it on $4 generic lists. No copay cards or manufacturer programs are needed because the drug's base cost is already minimal. A 2023 GoodRx analysis found the average cash price for lisinopril 10 mg #30 was $7.12 across U.S. pharmacies.

The cost differential is not trivial. Over a 5-year treatment horizon, a Medicare patient on Repatha without supplemental coverage faces cumulative out-of-pocket expenditure between $8,000 and $15,000, while lisinopril totals $240-$900 over the same period. For commercially insured patients with copay card access, the gap narrows substantially, but formulary position still determines administrative burden.

Insurance Coverage and Prior Authorization

Repatha requires prior authorization (PA) from virtually all major commercial payers, Medicare Advantage plans, and Part D sponsors. The typical PA criteria include documented ASCVD or familial hypercholesterolemia (FH), failure of maximally tolerated statin therapy, and an LDL-C threshold (commonly >70 mg/dL for ASCVD or >100 mg/dL for primary prevention with FH). According to a 2022 analysis published in the Journal of Managed Care & Specialty Pharmacy, PCSK9 inhibitor PA approval rates range from 50-75% on first submission (Baum et al., JMCP 2022).

Lisinopril sits on Tier 1 of nearly every formulary in the United States. It requires no prior authorization, no step therapy, and no quantity limits at standard doses (2.5-40 mg daily). The American Heart Association identifies ACE inhibitors as first-line therapy for hypertension with compelling indications including heart failure, post-MI, and diabetic nephropathy (Whelton et al., 2017 ACC/AHA Guidelines).

The administrative friction matters clinically. A 2021 study found that 29% of patients prescribed a PCSK9 inhibitor abandoned the prescription after PA denial or delay, compared to less than 3% abandonment for generic ACE inhibitors (Navar et al., JAMA Cardiology 2021).

Clinical Efficacy: What Each Drug Actually Does

These medications work through entirely separate mechanisms. Comparing their "efficacy" requires acknowledging they target different endpoints.

Repatha (evolocumab) binds circulating PCSK9 protein, preventing degradation of hepatic LDL receptors. The result: LDL-C drops 55-60% from baseline when added to statin therapy. In FOURIER (N=27,564 patients with established ASCVD), evolocumab reduced the composite of cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization by 15% over a median 2.2 years (HR 0.85 to 95% CI 0.79-0.92, P<0.001) (Sabatine et al., NEJM 2017). The number needed to treat (NNT) was 67 over 2.2 years for the primary endpoint.

Lisinopril inhibits angiotensin-converting enzyme, reducing angiotensin II production, lowering peripheral vascular resistance, and decreasing blood pressure by an average of 8-10 mmHg systolic. In ALLHAT (N=33,357), lisinopril performed equivalently to chlorthalidone for the primary endpoint of fatal coronary heart disease or nonfatal MI (RR 0.99 to 95% CI 0.91-1.08), though it showed higher rates of stroke (RR 1.15) and combined CVD (RR 1.10) compared to the diuretic arm (ALLHAT Officers, JAMA 2002).

Dr. Steven Nissen, Cleveland Clinic's Chief Academic Officer of Cardiovascular Medicine, noted in a 2019 interview with the American College of Cardiology: "PCSK9 inhibitors fill a gap that no oral generic can address. For patients who cannot reach LDL goals on statins alone, these are the only agents with proven outcomes data showing additional MACE reduction."

Who Needs Repatha and Who Needs Lisinopril

The clinical scenarios rarely overlap in a way that forces a choice between one or the other. Most patients who qualify for Repatha also take an ACE inhibitor or ARB concurrently because their cardiometabolic risk profile demands both LDL-C and blood pressure optimization.

Repatha is indicated for:

• Adults with established ASCVD needing additional LDL-C lowering beyond maximally tolerated statin
• Adults and adolescents (12+) with heterozygous familial hypercholesterolemia
• Adults with homozygous familial hypercholesterolemia
• Primary prevention in patients at high cardiovascular risk unable to reach LDL targets

Lisinopril is indicated for:

• Hypertension (first-line per ACC/AHA 2017 guidelines for patients with compelling indications)
• Heart failure with reduced ejection fraction (HFrEF)
• Post-myocardial infarction for cardiac remodeling prevention
• Diabetic nephropathy (proteinuria reduction)

The 2018 AHA/ACC Cholesterol Guidelines recommend PCSK9 inhibitors specifically for patients with LDL-C ≥70 mg/dL on maximally tolerated statin plus ezetimibe who have very high-risk ASCVD features (Grundy et al., Circulation 2019).

Access Strategies for Repatha

Navigating Repatha coverage requires a systematic approach. Here is what works.

Step 1: Document statin intolerance or inadequate response. Most payers require 8-12 weeks on at least two statins (or documented intolerance) plus ezetimibe before approving a PCSK9 inhibitor.

Step 2: Use the correct diagnosis codes. ICD-10 codes E78.01 (familial hypercholesterolemia) and I25.10 (ASCVD) trigger different PA pathways with different approval likelihoods.

Step 3: Submit a peer-to-peer review if initially denied. Overturn rates after peer-to-peer conversations range from 40-60% according to specialty pharmacy data reported by the National Lipid Association.

Step 4: Enroll in Amgen's support programs. The Repatha Ready copay card covers up to $150/month in out-of-pocket costs for eligible commercially insured patients. For uninsured patients, Amgen's Safety Net Foundation provides free drug for those earning below 300% of the federal poverty level.

Step 5: Consider biosimilar entry. The first evolocumab biosimilar applications are under FDA review as of early 2026, which may reduce costs 20-40% upon market entry based on precedent from adalimumab biosimilar pricing trends reported by the FDA (FDA Biosimilar Action Plan).

Access for Lisinopril: Minimal Barriers

Lisinopril access requires almost no navigation. The drug is available at every retail pharmacy in the U.S., covered by every insurance plan without prior authorization, and included on $4 generic lists at Walmart, Costco, Kroger, and others. Mail-order 90-day supplies typically cost $8-$12.

For uninsured patients, lisinopril is affordable without any assistance programs. The Mark Cuban Cost Plus Drug Company prices lisinopril 10 mg #90 at approximately $4.50 (drug cost plus 15% margin plus $5 dispensing fee).

The only access consideration: patients with a history of angioedema (especially those of African descent, who have 3-4x higher angioedema risk with ACE inhibitors per a meta-analysis in Hypertension 2012 (Brown et al.)) should use an ARB instead.

Safety and Tolerability Differences

Both drugs have favorable safety profiles, but the side-effect burden differs meaningfully.

Repatha's most common adverse events in FOURIER were injection-site reactions (2.1% vs 1.6% placebo), upper respiratory infections, and nasopharyngitis. No signal for neurocognitive adverse events emerged in the EBBINGHAUS substudy (N=1,974), which used Cambridge Neuropsychological Test Automated Battery assessments over 19 months (Giugliano et al., NEJM 2017). Repatha does not interact with hepatic cytochrome P450 enzymes, making drug-drug interactions rare.

Lisinopril's main tolerability issue is dry cough, occurring in 5-20% of patients due to bradykinin accumulation. Hyperkalemia risk increases in patients with CKD stage 3+ or those on potassium-sparing agents. Angioedema is rare (0.1-0.5%) but potentially life-threatening (Banerji et al., J Allergy Clin Immunol Pract 2017). Lisinopril is absolutely contraindicated in pregnancy (Category D/X per prior FDA classification).

Long-Term Cardiovascular Outcomes: Indirect Comparison

Since no head-to-head trial exists, indirect comparisons carry inherent limitations. Still, the available data provide context.

FOURIER's open-label extension (FOURIER-OLE) followed 6,635 patients for a median 5 years total. Extended evolocumab use showed a 15% reduction in cardiovascular death (HR 0.85 to 95% CI 0.75-0.96, P=0.008), a finding not statistically significant during the initial 2.2-year blinded period (O'Donoghue et al., Circulation 2022).

ALLHAT's lisinopril arm demonstrated no mortality benefit over chlorthalidone at 4.9 years mean follow-up. Post-hoc analyses suggested lisinopril may have specific advantages in patients with diabetes and metabolic syndrome, though the primary analysis did not show superiority for any lipid or BP endpoint versus the diuretic comparator.

The ACC/AHA 2019 risk calculator estimates that a patient with LDL-C 130 mg/dL and systolic BP 150 mmHg gains approximately 3-4% absolute 10-year ASCVD risk reduction from optimizing BP to goal, and an additional 2-3% from aggressive LDL lowering to <55 mg/dL. Both interventions are additive, not competitive.

Cost-Effectiveness Evidence

The Institute for Clinical and Economic Review (ICER) evaluated PCSK9 inhibitors in 2017 and updated their assessment in 2023. At the original list price ($14,100/year), evolocumab's incremental cost-effectiveness ratio (ICER) exceeded $300,000 per quality-adjusted life year (QALY). After Amgen's 2018 price reduction to approximately $5,850/year, the ICER fell to $85,000-$150,000/QALY depending on the patient population. For very high-risk secondary prevention patients (recurrent events within 2 years), the ICER approaches $50,000/QALY, which most U.S. payers consider cost-effective (Kazi et al., JAMA 2017).

Lisinopril has never required a formal cost-effectiveness analysis because its cost is negligible relative to its clinical benefit. At $48-$180 per year, even modest blood pressure reductions of 5-8 mmHg systolic produce ICERs well below $5,000/QALY, making it one of the most cost-effective cardiovascular interventions available.

The 2019 ACC/AHA guidelines explicitly incorporate cost into their treatment algorithm: "Clinicians should discuss the potential for ASCVD risk-reduction benefits, side effects, and drug-drug interactions, as well as the cost of therapy" (Grundy et al., Circulation 2019).

Practical Decision Framework for Clinicians

When cardiometabolic risk reduction is the goal, the decision tree follows established guidelines rather than a binary choice between these two agents.

For a patient with hypertension alone (no ASCVD, LDL at goal on statin): lisinopril or another first-line antihypertensive is appropriate. Repatha has no role.

For a patient with established ASCVD, LDL-C at goal, and uncontrolled BP: lisinopril (or ARB if ACE-intolerant) addresses the remaining modifiable risk factor. Repatha adds no benefit if LDL is already <55 mg/dL.

For a patient with established ASCVD, LDL-C persistently >70 mg/dL on maximally tolerated statin + ezetimibe, and controlled BP: Repatha is guideline-directed next-step therapy. The cost and access barriers become worth navigating because the residual cardiovascular risk from elevated LDL-C is quantifiable and treatable.

For a patient with both uncontrolled BP and persistently elevated LDL-C on maximum oral therapy: both drugs are indicated simultaneously. Start lisinopril first (immediate availability, low cost, rapid BP effect within 1-2 weeks), then pursue Repatha PA while the patient stabilizes on the antihypertensive regimen. This sequencing minimizes treatment gaps caused by insurance delays.

Dr. Pamela Morris, Medical University of South Carolina and past chair of the ACC Prevention Section, stated in ACC.org's Expert Analysis (2020): "We should not let the prior authorization process delay evidence-based therapy. Start what you can start immediately, then advocate for what the patient needs through the formulary system."

The Biosimilar Horizon

Evolocumab's core composition-of-matter patent expires in 2028-2029 in the U.S. However, biologics pathway (351(k)) applications for evolocumab biosimilars have been filed, and the first biosimilar approvals may arrive by 2027-2028. Based on the adalimumab biosimilar experience (Humira biosimilars entered at 55-85% of reference product WAC), evolocumab biosimilar pricing could fall to $2,500-$4,000/year.

This price reduction would shift the cost-effectiveness calculus substantially, potentially making PCSK9 inhibition accessible to a broader patient population beyond the current very-high-risk ASCVD niche. The Inflation Reduction Act's Medicare Part D redesign (effective 2025) already caps annual out-of-pocket spending at $2,000, which provides meaningful relief for Medicare beneficiaries currently paying specialty-tier copays for Repatha.